DGAP-News: Marinomed Biotech AG continues its growth path and reports strong financials in H1 2022
Korneuburg, Austria, 25 August 2022 Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, reported today financial results for the first half of the financial year 2022.
- Korneuburg, Austria, 25 August 2022 Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, reported today financial results for the first half of the financial year 2022.
- Pascal Schmidt, CFO of Marinomed, said: On the financial side, we continue to deliver strong quarterly results with once again high Carragelose revenues.
- In February 2022, Marinomed met all related milestones and received the final tranche of 6m under the financing agreement with EIB.
- Net loss for the period was 3.8m compared to 4.4m in H1 2021, in line with the companys business plan.